Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where

BusinesswireApr 12 16:15 ET

Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst

Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to preserve muscle l

BenzingaMar 28 14:42 ET

Express News | Scholar Rock Holding Shares Are Trading Higher After Raymond James Initiated Coverage on the Stock With a Strong Buy Rating and Announced a $30 Price Target

Moomoo 24/7Mar 28 12:36 ET

Raymond James Initiates Coverage On Scholar Rock Holding With Strong Buy Rating, Announces Price Target of $30

Raymond James analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy rating and announces Price Target of $30.

BenzingaMar 28 07:16 ET

Scholar Rock Holding Price Target Maintained With a $28.00/Share by Piper Sandler

Scholar Rock Holding Price Target Maintained With a $28.00/Share by Piper Sandler

Dow JonesMar 26 08:37 ET

Express News | Piper Sandler Maintains Overweight on Scholar Rock Holding, Maintains $28 Price Target

Moomoo 24/7Mar 26 08:27 ET